<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Urol</journal-id><journal-id journal-id-type="iso-abbrev">World J Urol</journal-id><journal-title-group><journal-title>World Journal of Urology</journal-title></journal-title-group><issn pub-type="ppub">0724-4983</issn><issn pub-type="epub">1433-8726</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25155034</article-id><article-id pub-id-type="pmc">4480825</article-id><article-id pub-id-type="publisher-id">1377</article-id><article-id pub-id-type="doi">10.1007/s00345-014-1377-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effects of tadalafil once daily or on demand versus placebo on time to recovery of erectile function in patients after bilateral nerve-sparing radical prostatectomy</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Moncada</surname><given-names>Ignacio</given-names></name><address><phone>+34 629057026</phone><email>ignacio@moncada.name</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>de Bethencourt</surname><given-names>Ferm&#x000ed;n R.</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Lled&#x000f3;-Garc&#x000ed;a</surname><given-names>Enrique</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Romero-Otero</surname><given-names>Javier</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Turbi</surname><given-names>Carmen</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>B&#x000fc;ttner</surname><given-names>Hartwig</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Henneges</surname><given-names>Carsten</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Martinez Salamanca</surname><given-names>Juan I.</given-names></name><xref ref-type="aff" rid="Aff7"/></contrib><aff id="Aff1"><label/>Department of Urology, Hospital La Zarzuela, Madrid, Spain </aff><aff id="Aff2"><label/>Department of Urology, Hospital &#x0201c;La Paz&#x0201d;, Madrid, Spain </aff><aff id="Aff3"><label/>Departament of Urology, Hospital General Universitario Gregorio Mara&#x000f1;&#x000f3;n, Madrid, Spain </aff><aff id="Aff4"><label/>Department of Urology, Hospital Universitario 12 Octubre, Madrid, Spain </aff><aff id="Aff5"><label/>Eli Lilly and Company, Madrid, Spain </aff><aff id="Aff6"><label/>Lilly Deutschland GmbH, Bad Homburg, Germany </aff><aff id="Aff7"><label/>Department of Urology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>8</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>8</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><volume>33</volume><issue>7</issue><fpage>1031</fpage><lpage>1038</lpage><history><date date-type="received"><day>31</day><month>3</month><year>2014</year></date><date date-type="accepted"><day>5</day><month>8</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2014</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p>We report time to erectile function (EF)-recovery data from a multicenter, randomized, double-blind, double-dummy, placebo-controlled trial evaluating tadalafil started after bilateral nerve-sparing radical prostatectomy (nsRP).</p></sec><sec><title>Methods</title><p>Patients &#x02264;68&#x000a0;years were randomized post-nsRP 1:1:1 to 9-month double-blind treatment (DBT) with tadalafil 5&#x000a0;mg once daily (OaD), 20&#x000a0;mg tadalafil on demand (&#x0201c;pro-re-nata&#x0201d;; PRN), or placebo, followed by 6-week drug-free washout (DFW) and 3-month open-label OaD treatment. Secondary outcome measures included Kaplan&#x02013;Meier estimates of time to EF-recovery (IIEF-EF&#x000a0;&#x02265;&#x000a0;22) during DBT (Cox proportional hazard model adjusting for treatment, age, and country).</p></sec><sec><title>Results</title><p>A total of 423 patients were randomized to tadalafil OaD (<italic>N</italic>&#x000a0;=&#x000a0;139), PRN (<italic>N</italic>&#x000a0;=&#x000a0;143), and placebo (<italic>N</italic>&#x000a0;=&#x000a0;141); 114/122/155 completed DBT. The proportion of patients achieving IIEF-EF &#x02265;22 at some point during DBT with OaD, PRN, and placebo was 29.5, 23.9, and 18.4&#x000a0;%, respectively. DBT was too short to achieve EF-recovery (IIEF-EF&#x000a0;&#x02265;&#x000a0;22) in &#x0003e;50&#x000a0;% of patients; median time to EF-recovery was non-estimable. Time for 25&#x000a0;% of patients to achieve EF-recovery (95&#x000a0;% CI) was 5.8 (4.9, 9.2) months for OaD versus 9.0 (5.5, 9.2) and 9.3 (9.0, 9.9)&#x000a0;months for PRN and placebo, respectively. Showing a significant overall treatment effect (<italic>p</italic>&#x000a0;=&#x000a0;0.038), the probability for EF-recovery was significantly higher for OaD versus placebo [hazard ratio (HR); 95&#x000a0;% CI 1.9; 1.2, 3.1; <italic>p</italic>&#x000a0;=&#x000a0;0.011], but not for PRN versus placebo (<italic>p</italic>&#x000a0;=&#x000a0;0.140). Of 57 OaD patients (41.0&#x000a0;%) with ED improved (by &#x02265;1 IIEF-EF severity grade) at the end of DBT, 16 (28.1&#x000a0;% of 57) maintained this improvement through DFW and 27 (47.4&#x000a0;%) declined but maintained improvement from baseline after DFW.</p></sec><sec><title>Conclusions</title><p>Data suggest that the use of tadalafil OaD can significantly shorten the time to EF-recovery post-nsRP compared with placebo.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s00345-014-1377-3) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Nerve-sparing prostatectomy</kwd><kwd>Penile function</kwd><kwd>Phosphodiesterase 5 inhibitors</kwd><kwd>Prostate cancer</kwd><kwd>Rehabilitation</kwd><kwd>Tadalafil once a day</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Berlin Heidelberg 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Erectile dysfunction (ED) can be a relatively common sequela after radical prostatectomy for localized prostate cancer [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>], despite the use of nerve-sparing techniques (nsRP). Many men may not recover erectile function (EF) for more than 18&#x000a0;months post-nsRP [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Rarely, time to EF-recovery can extend well beyond 2&#x000a0;years [<xref ref-type="bibr" rid="CR6">6</xref>]. The rate of and time to EF-recovery post-nsRP can vary widely and may be influenced by a number of factors, including patient age, type of surgery, and treatment during the recovery phase [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>Phosphodiesterase type 5 (PDE5)-inhibitors are generally well-tolerated and effective in the treatment of ED post-nsRP [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. However, they are less effective in the post-nsRP population when compared to the general population, and the optimal time point for starting PDE5-inhibitor treatment is still undetermined [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>To date, four randomized clinical trials (RCTs) have evaluated the impact of the early use of short-acting PDE5-inhibitors on EF-recovery in men post-nsRP. Sildenafil, vardenafil, and avanafil have all been shown to improve drug-assisted EF when given on demand (&#x0201c;pro-re-nata,&#x0201d; PRN) [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. However, EF-recovery up to 1&#x000a0;year post-nsRP did not differ between sildenafil given once daily (OaD) or PRN [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p>For the long-acting PDE5-inhibitor tadalafil, an initial retrospective study in 92 patients showed that tadalafil OaD started early after robot-assisted laparoscopic nsRP was well tolerated and significantly improved EF compared to patients without PDE5-inhibitor treatment [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p>Montorsi et al. [<xref ref-type="bibr" rid="CR15">15</xref>] have published a randomized, placebo-controlled trial evaluating the early use of tadalafil, given OaD or PRN, on both drug-assisted EF after 9&#x000a0;months of double-blind treatment (DBT) with tadalafil OaD or PRN and on unassisted EF (without PDE5-inhibitor support) after 6&#x000a0;weeks of drug-free washout (DFW) in men who developed ED post-nsRP. Tadalafil OaD improved drug-assisted EF-recovery, as measured by the proportion of patients achieving an International Index of Erectile Function-Erectile Function domain score (IIEF-EF) &#x02265;22 at the end of DBT, while unassisted EF-recovery after DFW was not improved by tadalafil OaD or PRN [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p>This paper specifically addresses the effects of tadalafil OaD and PRN treatment on the time to recovery of EF (IIEF-EF&#x000a0;&#x02265;&#x000a0;22) during the DBT period of this trial and the maintenance of treatment response after DFW.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Patients</title><p>Adult men aged &#x0003c;68&#x000a0;years at the time of nsRP with normal preoperative EF who underwent nsRP for organ-confined, non-metastatic prostate cancer (Gleason score &#x02264;7, prostate specific antigen &#x0003c;10&#x000a0;ng/mL) were enrolled between November 2009 and August 2011 in 50 centers from nine European countries and Canada (NCT01026818). Post-surgical inclusion criteria included the development of ED, as measured by a patient-reported Residual Erection Function (REF) score of &#x02264;3 (&#x0201c;penis is hard enough for penetration but not completely hard&#x0201d;). This criterion was used because of the limited validity of IIEF-EF domain scores for direct EF assessment post-nsRP [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Detailed eligibility criteria have been published [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec4"><title>Trial design</title><p>This multicenter, Phase IV, randomized, double-blind, 3-arm, placebo-controlled parallel-group trial consisted of the following periods, as previously described (Supplementary Figure S1) [<xref ref-type="bibr" rid="CR15">15</xref>]: screening (including nsRP surgery), 9-month randomized, double-blind, double-dummy treatment with 5&#x000a0;mg tadalafil OaD, 20&#x000a0;mg tadalafil PRN, or placebo (DBT); 6-week DFW; and 3-month open-label treatment with 5&#x000a0;mg/day tadalafil OaD (OLT, all patients).</p></sec><sec id="Sec5"><title>Outcome measures</title><sec id="Sec6"><title>IIEF-EF scores</title><p>The primary objective was to evaluate the efficacy of tadalafil OaD and tadalafil PRN, compared with placebo, in improving unassisted EF (EF after 6&#x000a0;weeks of DFW), as measured by the proportion of patients achieving an IIEF-EF score &#x02265;22 at the end of DFW (primary outcome) [<xref ref-type="bibr" rid="CR15">15</xref>]. An IIEF-EF &#x02265;22 was required at screening (after cancer diagnosis, &#x02264;6&#x000a0;weeks pre-nsRP). This cutoff was considered appropriate because many men with newly diagnosed prostate cancer claim to have unimpaired EF, but have IIEF-EF scores of 22&#x02013;25 (mild ED) [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. <italic>Time to EF</italic>-<italic>recovery</italic> (additional secondary analysis pre-specified in the statistical analysis plan, finalized and approved before database lock) was defined as the time from baseline to reach an IIEF-EF &#x02265;22 during DBT.</p></sec><sec id="Sec7"><title>ED severity</title><p>IIEF-EF scores were categorized into the following ED severity categories: severe (0&#x02013;10), moderate (11&#x02013;16), mild (17&#x02013;25), and normal (26&#x02013;30) [<xref ref-type="bibr" rid="CR18">18</xref>]. ED severity was assessed at baseline, end of DBT, and end of DFW. Improvement was defined as an IIEF-EF score of &#x02265;1 category higher than baseline (or maintaining normal EF) at the end of DBT. Maintenance of treatment response, assessed for patients who improved &#x02265;1 category after DBT, was defined as either maintaining this improved category until the end of DFW or declining after DBT but still maintaining a higher category at the end of DFW than at baseline.</p></sec></sec><sec id="Sec8"><title>Statistical analysis</title><p>The planned sample size of 412 patients was based on the primary outcome (proportion of patients achieving IIEF-EF &#x02265;22) [<xref ref-type="bibr" rid="CR15">15</xref>]. All analyses were based on the intent-to-treat (ITT) population, including all randomized patients with baseline data and at least one post-baseline visit. Pre-specified treatment group comparisons were tadalafil OaD versus placebo and tadalafil PRN versus placebo.</p><p>The Kaplan&#x02013;Meier product-limit method was used to estimate rates for the time to EF-recovery (IIEF-EF&#x000a0;&#x02265;&#x000a0;22) including 95&#x000a0;% confidence intervals (CI). Only patients with IIEF-EF &#x0003c;22 at screening were included; patients not reaching IIEF-EF &#x02265;22 were censored at the end of DBT. Hazard ratios (HRs) and <italic>p</italic> values were derived from a Cox proportional hazard model adjusting for treatment, age (&#x0003c;61&#x000a0;years vs. 61&#x02013;68&#x000a0;years), and country.</p><p>IIEF-EF score changes from baseline were analyzed using a mixed model for repeated measures (MMRM) analysis, assuming an unstructured covariance structure and including visit, treatment, treatment-by-visit interaction, country, age group, and baseline as fixed effects, and patient and error as random effects. Adjusted least square means (LSmeans) and 95&#x000a0;% CIs were calculated from the model. A minimally clinically important difference (MCID), defined as &#x02265;4&#x000a0;points difference in IIEF-EF [<xref ref-type="bibr" rid="CR19">19</xref>], was used to determine the average needed treatment effect that has clinical relevance for patients.</p><p>For <italic>p</italic> values, a 5&#x000a0;% level of significance was used. Data were analyzed using the SAS 9.2 software (SAS Institute Inc., Cary, USA).</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>Patient disposition and baseline characteristics</title><p>Of 583 patients screened, 423 were randomized: 139 (32.9&#x000a0;%) to tadalafil OaD, 143&#x000a0;(33.8&#x000a0;%) to tadalafil PRN, and 141 (33.3&#x000a0;%) to placebo (Supplementary Figure S2). Patients in the PRN group took a mean (SD) of 1.5 (0.95) tadalafil 20&#x000a0;mg tablets per week. Patient disposition, baseline demographics, and relevant disease characteristics were balanced in all 3&#x000a0;treatment groups (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR15">15</xref>]. As per inclusion criteria, all patients had to have IIEF-EF &#x02265;22 pre-nsRP. Post-nsRP at baseline, 83.9&#x000a0;% of patients reported severe ED based on IIEF-EF scores (mean [standard deviation; SD] score 6.4 [5.81]) and &#x0003e;98&#x000a0;% reported an REF &#x02264;3.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics and status post nsRP</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="left">Tadalafil OaD (<italic>N</italic>&#x000a0;=&#x000a0;139)</th><th align="left">Tadalafil PRN (<italic>N</italic>&#x000a0;=&#x000a0;143)</th><th align="left">Placebo (<italic>N</italic>&#x000a0;=&#x000a0;141)</th></tr></thead><tbody><tr><td align="left" colspan="4">
<italic>Age</italic> (<italic>years</italic>)</td></tr><tr><td align="left">Mean (SD)</td><td align="left">58.6 (5.07)</td><td align="left">57.5 (5.91)</td><td align="left">57.6 (5.69)</td></tr><tr><td align="left">&#x0003c;61 (<italic>n</italic>, %)</td><td align="left">82 (59.0)</td><td align="left">85 (59.4)</td><td align="left">91 (64.5)</td></tr><tr><td align="left">61&#x02013;68 (<italic>n</italic>, %)</td><td align="left">57 (41.0)</td><td align="left">58 (40.6)</td><td align="left">50 (35.5)</td></tr><tr><td align="left" colspan="4">
<italic>Ethnicity</italic> (<italic>n</italic>, %)</td></tr><tr><td align="left">Caucasian</td><td align="left">137 (98.6)</td><td align="left">141 (98.6)</td><td align="left">138 (97.9)</td></tr><tr><td align="left" colspan="4">
<italic>BMI</italic> (kg/m<sup>2</sup>)</td></tr><tr><td align="left">Mean (SD)</td><td align="left">26.6 (2.97)</td><td align="left">26.9 (2.93)</td><td align="left">27.1 (3.08)</td></tr><tr><td align="left" colspan="4">
<italic>IIEF-EF</italic>
</td></tr><tr><td align="left">
<italic>N</italic> with data</td><td align="left">137</td><td align="left">140</td><td align="left">137</td></tr><tr><td align="left">Mean (SD)</td><td align="left">6.0 (5.80)</td><td align="left">6.7 (5.57)</td><td align="left">6.5 (6.08)</td></tr><tr><td align="left" colspan="4">
<italic>ED severity</italic> (<italic>IIEF-EF categories</italic>) (<italic>n</italic>, %)<sup>a</sup>
</td></tr><tr><td align="left">Missing</td><td align="left">2 (1.4)</td><td align="left">2 (1.4)</td><td align="left">4 (2.8)</td></tr><tr><td align="left">Normal (26&#x02013;30)</td><td align="left">4 (2.9)</td><td align="left">2 (1.4)</td><td align="left">2 (1.4)</td></tr><tr><td align="left">Mild (17&#x02013;25)</td><td align="left">5 (3.6)</td><td align="left">8 (5.6)</td><td align="left">9 (6.4)</td></tr><tr><td align="left">Moderate (11&#x02013;16)</td><td align="left">9 (6.5)</td><td align="left">10 (7.0)</td><td align="left">11 (7.8)</td></tr><tr><td align="left">Severe (0&#x02013;10)</td><td align="left">119 (85.6)</td><td align="left">120 (84.5)</td><td align="left">115 (81.6)</td></tr><tr><td align="left">REF&#x000a0;&#x02264;&#x000a0;3<sup>b</sup>
</td><td align="left">137 (98.6)</td><td align="left">138 (97.2)</td><td align="left">141 (100)</td></tr><tr><td align="left" colspan="4">
<italic>nsRP approach</italic> (<italic>n</italic>, %)</td></tr><tr><td align="left">Open surgery</td><td align="left">68 (48.9)</td><td align="left">65 (45.5)</td><td align="left">56 (39.7)</td></tr><tr><td align="left">Conventional laparoscopy</td><td align="left">29 (20.9)</td><td align="left">31 (21.7)</td><td align="left">28 (19.9)</td></tr><tr><td align="left">Robot-assisted laparoscopy</td><td align="left">31 (22.3)</td><td align="left">41 (28.7)</td><td align="left">44 (31.2)</td></tr><tr><td align="left">Other</td><td align="left">11 (7.9)</td><td align="left">6 (4.2)</td><td align="left">13 (9.2)</td></tr><tr><td align="left" colspan="4">
<italic>Total nerve-sparing score post-nsRP</italic> (<italic>n</italic>, %)</td></tr><tr><td align="left">Perfect (2)</td><td align="left">117 (84.2)</td><td align="left">116 (81.1)</td><td align="left">113 (80.1)</td></tr><tr><td align="left">Not perfect (&#x0003e;2)</td><td align="left">22 (15.8)</td><td align="left">27 (18.9)</td><td align="left">28 (19.9)</td></tr></tbody></table><table-wrap-foot><p>
<italic>BMI</italic> body mass index, <italic>ED</italic> erectile dysfunction, <italic>IIEF-EF</italic> International Index of Erectile Function-Erectile Function, <italic>N</italic> total number of patients, <italic>n</italic> number of patients, <italic>nsRP</italic> bilateral nerve-sparing prostatectomy, <italic>OaD</italic> once a day, <italic>PRN</italic> &#x0201c;pro-re-nata&#x0201d;/on demand, <italic>REF</italic> residual erectile function, <italic>SD</italic> standard deviation</p><p>
<sup>a</sup>Based on intent-to-treat population, excluding one patient from the tadalafil PRN group with no post-baseline data</p><p>
<sup>b</sup>Two patients in the tadalafil OaD group and two patients in the tadalafil PRN group had missing values</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Time to EF-recovery during DBT</title><p>The proportion of patients achieving IIEF-EF &#x02265;22 at any time point during DBT with OaD, PRN, and placebo was 29.5, 23.9, and 18.4&#x000a0;%, respectively. Based on the Kaplan&#x02013;Meier analysis, 25&#x000a0;% of patients achieved EF-recovery (IIEF-EF&#x000a0;&#x02265;&#x000a0;22) within 5.8&#x000a0;months for tadalafil OaD, 9.0&#x000a0;months for tadalafil PRN, and 9.3&#x000a0;months for placebo (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). Median time to EF-recovery could not be estimated as &#x0003c;50&#x000a0;% of patients achieved EF-recovery during the 9-month DBT period (Supplementary Figure S3). The Cox proportional hazard model showed a significant overall treatment effect (<italic>p</italic>&#x000a0;=&#x000a0;0.038). Patients in the tadalafil OaD (but not PRN) group had a significantly higher probability for EF-recovery versus placebo (HR [95&#x000a0;% CI]: tadalafil OaD versus placebo: 1.90 [1.16, 3.12], <italic>p</italic>&#x000a0;=&#x000a0;0.011; tadalafil PRN versus placebo: 1.47 [0.88, 2.47], <italic>p</italic>&#x000a0;=&#x000a0;0.140). Age group had no significant effect on time to EF-recovery (<italic>p</italic>&#x000a0;=&#x000a0;0.223; Supplementary Figure S4).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>EF-recovery (IIEF-EF&#x000a0;&#x02265;&#x000a0;22) and EF category improvement during DBT. <italic>CI</italic> confidence interval, <italic>DBT</italic> double-blind treatment, <italic>EF</italic> erectile function, <italic>IIEF-EF</italic> International Index of Erectile Function-Erectile Function domain, <italic>LSmean</italic> least square mean, <italic>MCID</italic> minimal clinically important difference, <italic>MMRM</italic> mixed model for repeated measures, <italic>n</italic> number of events, <italic>N</italic> number of patients, <italic>n.e</italic>. not estimable, <italic>n.s.</italic> not significant, <italic>OaD</italic> once a day, <italic>PLC</italic> placebo, <italic>PRN</italic> &#x0201c;pro-re-nata&#x0201d;/on demand, <italic>TAD</italic> tadalafil, <italic>yrs</italic> years. <bold>a</bold> Event (EF-recovery) was defined as change in IIEF-EF from &#x0003c;22 at screening to &#x02265;22. <italic>P</italic> values are obtained from Cox proportional hazard model including terms for treatment, country, and age. <bold>b</bold>
<italic>p</italic> value obtained from an MMRM model, assuming an unstructured covariance structure, including terms for visit, treatment, treatment-by-visit interaction, country, age group, and baseline IIEF-EF score as fixed effects, and patient and error as random effects. Previously published in: Montorsi et al. 2014 [<xref ref-type="bibr" rid="CR15">15</xref>]</p></caption><graphic xlink:href="345_2014_1377_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec12"><title>LSmean IIEF-EF improvements</title><p>LSmean IIEF-EF improvement during DBT significantly exceeded the MCID (Lower 95&#x000a0;% CI LSmean &#x00394;IIEF-EF&#x000a0;&#x02265;&#x000a0;4) at month 5 in the tadalafil OaD treatment group (LSmean [95&#x000a0;% CI]: 6.9 [5.0, 8.8]) and month 9 in the tadalafil PRN treatment group (6.5 [4.6, 8.5]) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). For placebo, LSmean IIEF-EF did not significantly exceed the MCID before month 10.5 (end of DFW: 6.0 [3.9, 8.0]). The treatment effect versus placebo was statistically significant for tadalafil OaD only (LSmean difference [95&#x000a0;% CI]: 2.8 [0.8, 4.8]; <italic>p</italic>&#x000a0;=&#x000a0;0.007) at month 9.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Improvement and maintenance of improvement from baseline in ED severity (based on IIEF-EF categories). <italic>DBT</italic> double-blind treatment, <italic>DFW</italic> drug-free washout, <italic>ED</italic> erectile dysfunction, <italic>IIEF-EF</italic> International Index of Erectile Function-Erectile function domain, <italic>OaD</italic> once a day, <italic>PLC</italic>, placebo, <italic>PRN</italic> &#x0201c;pro-re-nata&#x0201d;/on demand, <italic>N</italic> total number of patients, <italic>n</italic> number of patients. IIEF-EF scores defining ED severity categories: severe, 0&#x02013;10; moderate, 11&#x02013;16; mild, 17&#x02013;25; normal, 26&#x02013;30. <italic>Improvement</italic> was defined as reporting an IIEF-EF score of at least 1&#x000a0;category higher than baseline (or maintaining normal EF). <italic>Improvement declined</italic> was defined as reporting IIEF-EF scores at the end of DFW that were less than the end of the DBT but still at least 1 category higher than baseline. <italic>Improvement maintained</italic> was defined as reporting IIEF-EF scores at the end of DFW that were at least as high or higher than scores at the end of DBT. <italic>Improvement lost</italic> was defined as IIEF-EF scores that were less than or equivalent to ED severity at baseline. All percentage are relative to the size of each treatment group (&#x0201c;N,&#x0201d; provided below <italic>each bar</italic>) not relative to the overall population. Missing data: For 33 patients (23.7&#x000a0;%) in the tadalafil OaD group, for 27 (19.0&#x000a0;%) in the tadalafil PRN group, and for 34 (24.1&#x000a0;%) in the placebo group, improvement could not be calculated because the patient either discontinued during DBT or had missing IIEF-EF scores at baseline and/or month 9. For three patients (5.3&#x000a0;%) in the tadalafil OaD group, one (1.8&#x000a0;%) in the tadalafil PRN group, and one (3.1&#x000a0;%) in the placebo group, maintenance of improvement could not be calculated because the patients either discontinued during DFW or had missing IIEF-EF scores at month 10.5</p></caption><graphic xlink:href="345_2014_1377_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec13"><title>ED severity improvement and maintenance of improvement</title><p>At baseline (randomization), 83.9&#x000a0;% of patients overall had severe ED (IIEF-EF 0&#x02013;10; Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). During DBT, improvement in ED severity by &#x02265;1 severity grade was achieved by 41.0&#x000a0;% of all tadalafil OaD patients, 38.7&#x000a0;% of all tadalafil PRN patients, and 22.7&#x000a0;% of patients on placebo (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). In all groups, the majority of those patients who had improved during DBT maintained an improvement of &#x02265;1 severity grade from baseline through DFW (improvement maintained, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). For tadalafil OaD (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>), 43 of 57 improved patients (75.4&#x000a0;%) were still improved from baseline after DFW, including 16 patients (28.1&#x000a0;%) who maintained the improvement they had reached at the end of DBT and 27 patients (47.4&#x000a0;%) who declined but still maintained improvement from baseline after DFW.</p></sec></sec><sec id="Sec14" sec-type="discussion"><title>Discussion</title><p>This trial was the first RCT in patients with established ED post-nsRP which investigated the effect of early treatment with tadalafil OaD and PRN on EF-recovery. As previously reported, tadalafil OaD significantly improved drug-assisted EF-recovery, as measured by the proportion of patients achieving IIEF-EF &#x02265;22 at the end of DBT (25.2&#x000a0;% of OaD patients versus 14.2&#x000a0;% in placebo group; <italic>p</italic>&#x000a0;=&#x000a0;0.016; Supplementary Figure S3). Unassisted EF-recovery after DFW was not improved by tadalafil OaD or PRN [<xref ref-type="bibr" rid="CR15">15</xref>]. Here, we show that tadalafil OaD (but not PRN) significantly shortened the time to EF-recovery during DBT when compared with placebo: with placebo, it took 9.3&#x000a0;months until 25&#x000a0;% of patients had reached EF-recovery; this period was shortened by 3.5&#x000a0;months (i.e., to 5.8&#x000a0;months) in the tadalafil OaD treatment group. An early start of penile rehabilitation does seem to be important; Mulhall et al. [<xref ref-type="bibr" rid="CR20">20</xref>] showed that patients who started PDE5-inhibitor treatment early post-nsRP reached significantly higher mean IIEF-EF scores than patients who started later at &#x02265;6&#x000a0;months post-nsRP (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001).</p><p>EF-recovery rates during 9-month DBT were &#x0003c;50&#x000a0;% in all treatment groups, which is in line with the published data on natural EF-recovery post-nsRP. Without treatment, time to EF-recovery averages 18&#x000a0;months [<xref ref-type="bibr" rid="CR4">4</xref>] and can extend well beyond 2&#x000a0;years [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. In a study by Gallina et al. [<xref ref-type="bibr" rid="CR21">21</xref>], only 35.8&#x000a0;% of untreated patients reached EF-recovery (IIEF-EF&#x000a0;&#x02265;&#x000a0;22) after an average of 26.8&#x000a0;months post-nsRP.</p><p>However, LSmean IIEF-EF improvement in the tadalafil OaD group significantly exceeded the MCID (&#x00394;IIEF-EF&#x000a0;&#x02265;&#x000a0;4 [<xref ref-type="bibr" rid="CR19">19</xref>]) already at month 5 of DBT, as compared to month 9 for tadalafil PRN; improvement with placebo did not significantly exceed the MCID before month 10.5 (end of DFW). At the end of DBT, the treatment effect versus placebo was statistically significant for tadalafil OaD only (<italic>p</italic>&#x000a0;=&#x000a0;0.007).</p><p>Chronic (daily) dosing of tadalafil, but not PRN treatment, will lead to steady state PDE5-inhibition [<xref ref-type="bibr" rid="CR22">22</xref>] which may be associated with prolonged (continuous) periods of increased tissue oxygenation during the post-operative regenerative process. Preclinical data suggest that chronic low-dose administration may protect from structural changes of penile cavernous corpora and is associated with EF enhancement [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>].</p><p>None of the other RCTs on PDE5-inhibitors post-nsRP has reported time to EF-recovery data based on Kaplan&#x02013;Meier analysis. However, data from 2 non-RCTs indicated that PDE5-inhibitor treatment may shorten time to EF-recovery [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Bannowsky et al. [<xref ref-type="bibr" rid="CR26">26</xref>] reported a significant difference in time to EF-recovery between patients receiving nightly low-dose sildenafil for up to 12&#x000a0;months when compared with patients receiving no treatment (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). In agreement with these results, Briganti et al. showed that patients receiving any PDE5-inhibitor (OaD or PRN) achieved significantly higher 3-year EF-recovery rates (IIEF-EF&#x000a0;&#x02265;&#x000a0;22) than patients receiving placebo (72 vs. 38&#x000a0;%, <italic>p</italic>&#x000a0;&#x02264;&#x000a0;0.001, Kaplan&#x02013;Meier analysis). For the overall population studied, no significant difference was observed between OaD and PRN treatment. However, patients with an intermediate risk of ED (66&#x02013;69&#x000a0;years or IIEF-EF 11&#x02013;25, and Charlson Comorbidity Index &#x02264;1), who shared key criteria with our patient population of low/intermediate ED risk (average patient &#x02264;61&#x000a0;years; IIEF-EF&#x000a0;&#x02265;&#x000a0;22 at baseline), achieved significantly higher 3-year EF-recovery rates with OaD compared to PRN treatment (74 vs. 52&#x000a0;%; <italic>p</italic>&#x000a0;=&#x000a0;0.02) [<xref ref-type="bibr" rid="CR27">27</xref>]. As suggested by Castiglione et al. [<xref ref-type="bibr" rid="CR28">28</xref>], the effect of PDE5-inhibitor treatment post-nsRP may be maximal in patients with intermediate ED risk. To date, trials have focused on populations with low ED risk [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>].</p><p>In our trial, age group had no significant effect on the time to EF-recovery during DBT or on the proportion of patients achieving EF-recovery during DBT [<xref ref-type="bibr" rid="CR15">15</xref>]. However, after DFW (Month 10.5), younger patients (&#x0003c;61&#x000a0;years) were significantly more probable to achieve EF-recovery than older patients (<italic>p</italic>&#x000a0;=&#x000a0;0.020; [<xref ref-type="bibr" rid="CR15">15</xref>]). These results are in line with literature.</p><p>A 2010 study by Briganti et al. [<xref ref-type="bibr" rid="CR29">29</xref>] showed that younger patients (&#x02264;65&#x000a0;years) were more likely to recover EF (IIEF-EF&#x000a0;&#x02265;&#x000a0;22) than older patients. A meta-analysis by Kilminster et al. and studies by Nelson et al. and Gallina et al. also showed that younger patients were significantly more likely to recover EF post-nsRP than older patients [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR21">21</xref>].</p><p>A clear limitation of the current trial was that the 9-month DBT phase was too short for full assessment of EF-recovery. We cannot exclude that the treatment effect of tadalafil OaD may be lost by the end of 2&#x000a0;years due to spontaneous EF-recovery in the placebo arm. Valid statistical analysis of time to EF-recovery could not be performed on IIEF-EF data collected after DBT (i.e., after DFW at month 10.5 or OLT at month 13.5) due to the break in ED treatment for 6&#x000a0;weeks. The significant treatment effect on EF-recovery was lost during the DFW. However, after 3-month OLT with tadalafil OaD (month 13.5), the proportion of patients with EF-recovery increased in all treatment groups (32.4&#x000a0;% in the tadalafil OaD group; 33.1&#x000a0;% in the tadalafil PRN group; and 27.0&#x000a0;% in the placebo group) [<xref ref-type="bibr" rid="CR15">15</xref>]. Further, the results of the Briganti study indicate that the significant effect of OaD treatment on time to recovery may persist after longer follow-up periods (up to 3&#x000a0;years) [<xref ref-type="bibr" rid="CR27">27</xref>]. In this context, the demonstrated maintenance of tadalafil&#x02019;s treatment effect could play an important role in future studies that allow for longer treatment or follow-up periods. Even after DFW, over 75&#x000a0;% of patients treated with tadalafil OaD maintained an improvement in ED severity from baseline.</p><p>In conclusion, patients taking tadalafil OaD (but not those taking PRN) significantly shortened the time to EF-recovery during DBT when compared with placebo. No statistically significant difference in time to EF-recovery was observed between younger and older patients. These data suggest that tadalafil OaD, if started early, may accelerate EF-recovery post-nsRP.
</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec15"><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="345_2014_1377_MOESM1_ESM.pdf"><caption><p>Supplementary material 1 (PDF 333&#x000a0;kb)</p></caption></media></supplementary-material></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CI</term><def><p>Confidence interval</p></def></def-item><def-item><term>DBT</term><def><p>Double-blind treatment</p></def></def-item><def-item><term>DFW</term><def><p>Drug-free washout</p></def></def-item><def-item><term>ED</term><def><p>Erectile dysfunction</p></def></def-item><def-item><term>EF</term><def><p>Erectile function</p></def></def-item><def-item><term>HR</term><def><p>Hazard ratio</p></def></def-item><def-item><term>IIEF-EF</term><def><p>International Index of Erectile Function-Erectile Function domain score</p></def></def-item><def-item><term>ITT</term><def><p>Intent-to-treat</p></def></def-item><def-item><term>LSmeans</term><def><p>Least square means</p></def></def-item><def-item><term>MCID</term><def><p>Minimally clinically important difference</p></def></def-item><def-item><term>MMRM</term><def><p>Mixed model for repeated measures</p></def></def-item><def-item><term>nsRP</term><def><p>Nerve-sparing radical prostatectomy</p></def></def-item><def-item><term>OaD</term><def><p>Once daily</p></def></def-item><def-item><term>OLT</term><def><p>Open-label OaD treatment</p></def></def-item><def-item><term>PDE5</term><def><p>Phosphodiesterase type 5</p></def></def-item><def-item><term>PRN</term><def><p>&#x0201c;Pro-re-nata,&#x0201d; on demand</p></def></def-item><def-item><term>RCTs</term><def><p>Randomized clinical trails</p></def></def-item><def-item><term>REF</term><def><p>Residual erection function</p></def></def-item><def-item><term>SD</term><def><p>Standard deviation</p></def></def-item></def-list></glossary><ack><p>We thank all patients for participating and all trial investigators for their contribution to data acquisition and patient care. We thank Julia Branicka and Tom Clayton, both Eli Lilly and Company, for supporting the conduct of the trial. We thank Joaquin Casariego and Kraig Kinchen, Eli Lilly and Company, for medical advice. We thank Clare Barker, Bruce Basson, Ann Gibb and Pepa Polavieja, all from Eli Lilly and Company, for statistical support. Statistical analyses were programmed by PSI CRO LTD, St. Petersburg, Russia. We thank Shawna Crawford and Karin Helsberg, Trilogy Writing and Consulting GmbH, Frankfurt, Germany, for providing medical writing services on behalf of Eli Lilly.</p><sec id="d30e1334"><title>Conflict of interest</title><p>The trial has been funded by Eli Lilly and Company. I. Moncada has been a consultant for and received speaker honoraria and travel expenses from Eli Lilly. C. Henneges, C. Turbi and H. Buettner are employees of Eli Lilly and Company and own Eli Lilly stock. F.R. de Bethencourt, E. Lled&#x000f3;-Garc&#x000ed;a, J.I Martinez-Salamanca and J. Romero-Otero have no conflicts of interest to disclose.</p></sec><sec id="d30e1339"><title>Ethical standard</title><p>The study was conducted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments; appropriate ethical review boards approved the trial protocol for each country. All patients had signed written informed consent prior to their inclusion in the study.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salonia</surname><given-names>A</given-names></name><name><surname>Burnett</surname><given-names>AL</given-names></name><name><surname>Graefen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prevention and management of postprostatectomy sexual dysfunctions. Part 1: choosing the right patient at the right time for the right surgery</article-title><source>Eur Urol</source><year>2012</year><volume>62</volume><fpage>261</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2012.04.046</pub-id><pub-id pub-id-type="pmid">22575909</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salonia</surname><given-names>A</given-names></name><name><surname>Burnett</surname><given-names>AL</given-names></name><name><surname>Graefen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prevention and management of postprostatectomy sexual dysfunctions. Part 2: recovery and preservation of erectile function, sexual desire, and orgasmic function</article-title><source>Eur Urol</source><year>2012</year><volume>62</volume><fpage>273</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2012.04.047</pub-id><pub-id pub-id-type="pmid">22575910</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ficarra</surname><given-names>V</given-names></name><name><surname>Novara</surname><given-names>G</given-names></name><name><surname>Ahlering</surname><given-names>TE</given-names></name><etal/></person-group><article-title>Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy</article-title><source>Eur Urol</source><year>2012</year><volume>62</volume><fpage>418</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2012.05.046</pub-id><pub-id pub-id-type="pmid">22749850</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanford</surname><given-names>JL</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Hamilton</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study</article-title><source>JAMA</source><year>2000</year><volume>283</volume><fpage>354</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1001/jama.283.3.354</pub-id><pub-id pub-id-type="pmid">10647798</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilminster</surname><given-names>S</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>S</given-names></name><name><surname>Menon</surname><given-names>M</given-names></name><name><surname>Joseph</surname><given-names>JV</given-names></name><name><surname>Ralph</surname><given-names>DJ</given-names></name><name><surname>Patel</surname><given-names>HRH</given-names></name></person-group><article-title>Predicting erectile function outcome in men after radical prostatectomy for prostate cancer</article-title><source>BJU Int</source><year>2011</year><volume>110</volume><fpage>422</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410X.2011.10757.x</pub-id><pub-id pub-id-type="pmid">22182202</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sivarajan</surname><given-names>G</given-names></name><name><surname>Prabhu</surname><given-names>V</given-names></name><name><surname>Taksler</surname><given-names>GB</given-names></name><name><surname>Laze</surname><given-names>J</given-names></name><name><surname>Lepor</surname><given-names>H</given-names></name></person-group><article-title>Ten-year outcomes of sexual function after radical prostatectomy: results of a prospective longitudinal study</article-title><source>Eur Urol</source><year>2014</year><volume>65</volume><fpage>58</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2013.08.019</pub-id><pub-id pub-id-type="pmid">24007711</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>CJ</given-names></name><name><surname>Scardino</surname><given-names>PT</given-names></name><name><surname>Eastham</surname><given-names>JA</given-names></name><name><surname>Mulhall</surname><given-names>JP</given-names></name></person-group><article-title>Back to baseline: erectile function recovery after radical prostatectomy from the patients&#x02019; perspective</article-title><source>J Sex Med</source><year>2013</year><volume>10</volume><fpage>1636</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.1111/jsm.12135</pub-id><pub-id pub-id-type="pmid">23551767</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montorsi</surname><given-names>F</given-names></name><name><surname>Nathan</surname><given-names>PH</given-names></name><name><surname>McCullough</surname><given-names>A</given-names></name><etal/></person-group><article-title>Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial</article-title><source>J Urol</source><year>2004</year><volume>172</volume><fpage>1036</fpage><lpage>1041</lpage><pub-id pub-id-type="doi">10.1097/01.ju.0000136448.71773.2b</pub-id><pub-id pub-id-type="pmid">15311032</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatzimouratidis</surname><given-names>K</given-names></name><name><surname>Burnett</surname><given-names>AL</given-names></name><name><surname>Hatzichristou</surname><given-names>D</given-names></name><name><surname>McCullough</surname><given-names>AR</given-names></name><name><surname>Montorsi</surname><given-names>F</given-names></name><name><surname>Mulhall</surname><given-names>JP</given-names></name></person-group><article-title>Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application</article-title><source>Eur Urol</source><year>2009</year><volume>55</volume><fpage>334</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2008.10.028</pub-id><pub-id pub-id-type="pmid">18986755</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathan</surname><given-names>PH</given-names></name><name><surname>McCullough</surname><given-names>AR</given-names></name><name><surname>Levine</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy</article-title><source>Int J Impot Res</source><year>2008</year><volume>20</volume><fpage>479</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1038/ijir.2008.33</pub-id><pub-id pub-id-type="pmid">18650827</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montorsi</surname><given-names>F</given-names></name><name><surname>Brock</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effect of nightly versus on demand vardenafil on recovery of erectile function in men following bilateral nervesparing radical prostatectomy</article-title><source>Eur Urol</source><year>2008</year><volume>54</volume><fpage>924</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2008.06.083</pub-id><pub-id pub-id-type="pmid">18640769</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulhall</surname><given-names>JP</given-names></name><name><surname>Burnett</surname><given-names>AL</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><etal/></person-group><article-title>A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy</article-title><source>J Urol</source><year>2013</year><volume>189</volume><fpage>2229</fpage><lpage>2236</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2012.11.177</pub-id><pub-id pub-id-type="pmid">23219537</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlovich</surname><given-names>CP</given-names></name><name><surname>Levinson</surname><given-names>AW</given-names></name><name><surname>Su</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Nightly vs on-demand sildenafil for penile rehabilitation after minimally invasive nerve-sparing radical prostatectomy: results of a randomized double-blind trial with placebo</article-title><source>BJU Int</source><year>2013</year><volume>112</volume><fpage>844</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1111/bju.12253</pub-id><pub-id pub-id-type="pmid">23937708</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>YE</given-names></name><name><surname>Kim</surname><given-names>SD</given-names></name><name><surname>Kim</surname><given-names>TH</given-names></name><name><surname>Sung</surname><given-names>GT</given-names></name></person-group><article-title>The efficacy and safety of tadalafil 5 mg once daily in the treatment of erectile dysfunction after robot-assisted laparoscopic radical prostatectomy: 1-year follow-up</article-title><source>Korean J Urol</source><year>2014</year><volume>55</volume><fpage>112</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.4111/kju.2014.55.2.112</pub-id><pub-id pub-id-type="pmid">24578807</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montorsi</surname><given-names>F</given-names></name><name><surname>Brock</surname><given-names>G</given-names></name><name><surname>Stolzenburg</surname><given-names>JU</given-names></name><etal/></person-group><article-title>Effects of tadalafil treatment on erectile function recovery post bilateral nerve-sparing radical prostatectomy: a randomized placebo-controlled study</article-title><source>Eur Urol</source><year>2014</year><volume>65</volume><fpage>587</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2013.09.051</pub-id><pub-id pub-id-type="pmid">24169081</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulhall</surname><given-names>JP</given-names></name><name><surname>Goldstein</surname><given-names>I</given-names></name><name><surname>Bushmakin</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Validation of the erection hardness score</article-title><source>J Sex Med</source><year>2007</year><volume>4</volume><fpage>1626</fpage><lpage>1634</lpage><pub-id pub-id-type="doi">10.1111/j.1743-6109.2007.00600.x</pub-id><pub-id pub-id-type="pmid">17888069</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cappelleri</surname><given-names>JC</given-names></name><name><surname>Rosen</surname><given-names>RC</given-names></name><name><surname>Smith</surname><given-names>MD</given-names></name><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Osterloh</surname><given-names>IH</given-names></name></person-group><article-title>Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function</article-title><source>Urology</source><year>1999</year><volume>54</volume><fpage>346</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/S0090-4295(99)00099-0</pub-id><pub-id pub-id-type="pmid">10443736</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porst</surname><given-names>H</given-names></name><name><surname>Glina</surname><given-names>S</given-names></name><name><surname>Ralph</surname><given-names>D</given-names></name><name><surname>Zeigler</surname><given-names>H</given-names></name><name><surname>Wong</surname><given-names>DG</given-names></name><name><surname>Woodward</surname><given-names>B</given-names></name></person-group><article-title>Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction</article-title><source>J Sex Med</source><year>2010</year><volume>7</volume><fpage>3487</fpage><lpage>3494</lpage><pub-id pub-id-type="doi">10.1111/j.1743-6109.2010.01908.x</pub-id><pub-id pub-id-type="pmid">20584129</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>RC</given-names></name><name><surname>Allen</surname><given-names>KR</given-names></name><name><surname>Ni</surname><given-names>X</given-names></name><name><surname>Araujo</surname><given-names>AB</given-names></name></person-group><article-title>Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale</article-title><source>Eur Urol</source><year>2011</year><volume>60</volume><fpage>1010</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2011.07.053</pub-id><pub-id pub-id-type="pmid">21855209</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulhall</surname><given-names>JP</given-names></name><name><surname>Parker</surname><given-names>M</given-names></name><name><surname>Waters</surname><given-names>BW</given-names></name><name><surname>Flanigan</surname><given-names>R</given-names></name></person-group><article-title>The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function</article-title><source>BJU Int</source><year>2010</year><volume>105</volume><issue>1</issue><fpage>37</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410X.2009.08775.x</pub-id><pub-id pub-id-type="pmid">19659465</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallina</surname><given-names>A</given-names></name><name><surname>Ferrari</surname><given-names>M</given-names></name><name><surname>Suardi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Erectile function outcome after bilateral nerve sparing radical prostatectomy: which patients may be left untreated?</article-title><source>J Sex Med</source><year>2012</year><volume>9</volume><fpage>903</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1111/j.1743-6109.2011.02622.x</pub-id><pub-id pub-id-type="pmid">22240189</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forgue</surname><given-names>ST</given-names></name><name><surname>Patterson</surname><given-names>BE</given-names></name><name><surname>Bedding</surname><given-names>AW</given-names></name><etal/></person-group><article-title>Tadalafil pharmacokinetics in healthy subjects</article-title><source>Br J Clin Pharmacol</source><year>2006</year><volume>61</volume><fpage>280</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2005.02553.x</pub-id><pub-id pub-id-type="pmid">16487221</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aydogdu</surname><given-names>O</given-names></name><name><surname>Gokce</surname><given-names>MI</given-names></name><name><surname>Burgu</surname><given-names>B</given-names></name><name><surname>Baltac&#x00131;</surname><given-names>S</given-names></name><name><surname>Yaman</surname><given-names>O</given-names></name></person-group><article-title>Tadalafil rehabilitation therapy preserves penile size after bilateral nerve sparing radical retropubic prostatectomy</article-title><source>Int Braz J Urol</source><year>2011</year><volume>37</volume><fpage>336</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1590/S1677-55382011000300007</pub-id><pub-id pub-id-type="pmid">21756381</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostafa</surname><given-names>ME</given-names></name><name><surname>Senbel</surname><given-names>AM</given-names></name><name><surname>Mostafa</surname><given-names>T</given-names></name></person-group><article-title>Effect of chronic low-dose tadalafil on penile cavernous tissues in diabetic rats</article-title><source>Urology</source><year>2013</year><volume>81</volume><fpage>1253</fpage><lpage>1259</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2012.12.068</pub-id><pub-id pub-id-type="pmid">23726447</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Ryu</surname><given-names>KS</given-names></name><name><surname>Li</surname><given-names>WJ</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Paick</surname><given-names>JS</given-names></name></person-group><article-title>Chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signalling in a rat model of diabetic erectile dysfunction</article-title><source>Eur Urol</source><year>2008</year><volume>53</volume><fpage>1282</fpage><lpage>1288</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2008.01.032</pub-id><pub-id pub-id-type="pmid">18243503</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bannowsky</surname><given-names>A</given-names></name><name><surname>Schulze</surname><given-names>H</given-names></name><name><surname>van der Horst</surname><given-names>C</given-names></name><name><surname>Hautmann</surname><given-names>S</given-names></name><name><surname>J&#x000fc;nemann</surname><given-names>KP</given-names></name></person-group><article-title>Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil</article-title><source>BJU Int</source><year>2008</year><volume>101</volume><fpage>1279</fpage><lpage>1283</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410X.2008.07515.x</pub-id><pub-id pub-id-type="pmid">18284406</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briganti</surname><given-names>A</given-names></name><name><surname>Di Trapani</surname><given-names>E</given-names></name><name><surname>Abdollah</surname><given-names>F</given-names></name><etal/></person-group><article-title>Choosing the best candidates for penile rehabilitation after bilateral nerve-sparing radical prostatectomy</article-title><source>J Sex Med</source><year>2012</year><volume>9</volume><fpage>608</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1111/j.1743-6109.2011.02580.x</pub-id><pub-id pub-id-type="pmid">22189164</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castiglione</surname><given-names>F</given-names></name><name><surname>Nini</surname><given-names>A</given-names></name><name><surname>Briganti</surname><given-names>A</given-names></name></person-group><article-title>Penile rehabilitation with phosphodiesterase type 5 inhibitors after nerve-sparing radical prostatectomy: are we targeting the right patients?</article-title><source>Eur Urol</source><year>2014</year><volume>65</volume><fpage>673</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2013.11.049</pub-id><pub-id pub-id-type="pmid">24388439</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briganti</surname><given-names>A</given-names></name><name><surname>Gallina</surname><given-names>A</given-names></name><name><surname>Suardi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Predicting erectile function recovery after bilateral nerve sparing radical prostatectomy: a proposal of a novel preoperative risk stratification</article-title><source>J Sex Med</source><year>2010</year><volume>7</volume><fpage>2521</fpage><lpage>2531</lpage><pub-id pub-id-type="pmid">20487236</pub-id></element-citation></ref></ref-list></back></article>